Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells

Leukemia. 2006 Sep;20(9):1629-32. doi: 10.1038/sj.leu.2404315. Epub 2006 Jul 13.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Dendritic Cells / drug effects*
  • Dendritic Cells / immunology
  • Flow Cytometry
  • Humans
  • Imatinib Mesylate
  • Immunophenotyping
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Piperazines / pharmacology*
  • Piperazines / therapeutic use
  • Pyrimidines / pharmacology*
  • Pyrimidines / therapeutic use

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate